What Is the Most Common Antibiotic for a UTI?

Nitrofurantoin is the most commonly recommended first-line antibiotic for uncomplicated urinary tract infections in current clinical guidelines. That wasn’t always the case. As recently as the early 2010s, fluoroquinolones like ciprofloxacin dominated UTI prescriptions in the United States, but rising resistance and serious side-effect concerns pushed them out of the top spot. The shift has reshaped how doctors think about a condition that sends millions of people to the clinic every year, and the “right” antibiotic for your UTI depends on more variables than most people realize.

How Nitrofurantoin Became the Go-To

Nitrofurantoin has been around since 1953, which makes it one of the older antibiotics still in regular use. For decades it played a supporting role while broader-spectrum drugs got the spotlight. What changed was a combination of two things: resistance patterns shifted against those broader drugs, and guidelines caught up with the evidence that nitrofurantoin still worked remarkably well against the bacteria that cause most bladder infections.¹ International guidelines now give nitrofurantoin a strong recommendation for uncomplicated cystitis, typically at a dose of 100 mg twice daily for five or more days.²

One reason nitrofurantoin has held up so well against resistance is that it concentrates almost entirely in the urine rather than circulating through the rest of the body. Bacteria have had fewer opportunities to develop resistance to it compared with drugs that are used for everything from bronchitis to skin infections. That narrow focus is a strength for bladder infections, but it also means nitrofurantoin is not a good fit for kidney infections or any UTI that has spread beyond the bladder, because the drug doesn’t reach therapeutic levels in the bloodstream or kidney tissue.

The picture looked very different a decade ago. A large analysis of U.S. outpatient prescribing between 2002 and 2011 found that fluoroquinolones were the most frequently prescribed antibiotics for uncomplicated UTIs, accounting for about half of all prescriptions.³ That era is effectively over for straightforward bladder infections, though ciprofloxacin and levofloxacin still get prescribed more than guidelines suggest they should.

Other First-Line Options

Nitrofurantoin isn’t the only antibiotic sitting in the first-line tier. Two alternatives share that recommendation in most major guidelines: fosfomycin and, in countries where it is available, pivmecillinam.

Fosfomycin stands out because it’s a single-dose treatment. You take one 3-gram packet of granules dissolved in water, and you’re done. A systematic review and meta-analysis found that single-dose fosfomycin was just as effective as multi-day courses of other antibiotics for clearing uncomplicated UTIs, with a similar rate of side effects.⁴ A head-to-head trial comparing it with a five-day course of ciprofloxacin found no meaningful difference in cure rates between the two.⁵ That one-dose convenience can make a real difference for people who struggle to finish a full course of pills. In France, fosfomycin is prescribed for roughly one in two women with uncomplicated cystitis, making it the dominant choice there.⁶

Pivmecillinam, recommended at 400 mg three times daily for at least three days, is widely used in Scandinavian countries but is harder to find in the United States and parts of Asia.² Where it is available, it carries a strong recommendation and has the advantage of being very well tolerated.

Trimethoprim-sulfamethoxazole, often called TMP-SMX or by brand names like Bactrim, was the classic UTI drug for years. It still works for many people, but resistance has climbed high enough in some areas that doctors can no longer prescribe it confidently without knowing the local resistance data. Hospital-based tracking of E. coli resistance found TMP-SMX resistance running between roughly 23% and 34% over a recent five-year period.⁷ In some patient groups, the picture is worse. Among people who had previously used TMP-SMX, resistance rose to about 31%, and for those with a prior history of resistant bacteria in their urinary tract, it jumped above 60%.⁸ That means if you’ve been treated with TMP-SMX before, it’s more likely to fail the next time around.

Why Fluoroquinolones Fell Out of Favor

Ciprofloxacin and levofloxacin are powerful antibiotics that work well against UTI-causing bacteria, so it’s fair to wonder why guidelines pulled them from the front line. The answer comes down to two problems that got worse over time.

First, resistance. A systematic review and meta-analysis of ciprofloxacin resistance in E. coli UTIs found that resistance rates have been climbing globally and concluded that using ciprofloxacin as the default empiric therapy should be reconsidered.⁹ Among E. coli samples tracked at one hospital system from 2019 to 2023, ciprofloxacin resistance ranged from about 21% to 32%.⁷ That’s roughly one in four infections not responding to the drug.

Second, the side-effect profile is disproportionate for a simple bladder infection. Both the FDA and the European Medicines Agency have issued warnings that fluoroquinolones carry risks of tendon damage, nerve damage, and mood changes that can sometimes be long-lasting. The regulatory position is blunt: these drugs should not be used for lower urinary tract infections unless no other treatment option is available, because the potential harms outweigh the benefits for a condition that is typically not dangerous.¹⁰ Guidelines updated in 2010 formally removed fluoroquinolones from first-line status because of what researchers call “collateral damage,” meaning the broader harm they do to resistance patterns, gut bacteria, and the risk of infections like C. difficile.¹¹

Despite all this, fluoroquinolones remain appropriate for more serious urinary infections like pyelonephritis, and they are still used as second-line options when first-line drugs can’t be tolerated or won’t work against the specific bacteria involved.

Cephalosporins as a Backup Plan

First-generation cephalosporins like cephalexin (Keflex) and cefadroxil are increasingly used when the top-tier options aren’t suitable. A critical review of these drugs concluded that they offer very good bacteriological and clinical cure rates for uncomplicated lower UTIs caused by the most common bacteria, comparable to many traditionally first-line agents.¹² At one institution that adopted cephalexin as its preferred oral antibiotic for empiric UTI treatment, about 81% of patients met criteria for clinical success.¹³

Cephalosporins sit a step below nitrofurantoin and fosfomycin in most guidelines, partly because they are broader-spectrum and thus have a slightly greater impact on gut bacteria. But they serve as a practical fluoroquinolone-sparing alternative, especially when a patient is allergic to sulfa drugs or can’t tolerate nitrofurantoin.

Complicated UTIs and Kidney Infections Need Different Drugs

Everything described above applies to uncomplicated cystitis, which is the medical term for a straightforward bladder infection in an otherwise healthy person. The treatment changes substantially once a UTI becomes “complicated,” meaning it involves the kidneys, occurs in someone with an abnormal urinary tract, is associated with a catheter, or happens in someone with a weakened immune system.

Kidney infections (pyelonephritis) need antibiotics that reach adequate concentrations in kidney tissue and the bloodstream, which immediately rules out nitrofurantoin and fosfomycin. Treatment courses also stretch longer, typically running 7 to 14 days compared with the 3 to 5 days used for simple cystitis.¹⁴ Fluoroquinolones and TMP-SMX are used in this setting when the bacteria are susceptible, and severe cases may require IV antibiotics in a hospital.

One study of antibiotic prescribing found that the type of antibiotic prescribed was appropriate in only about 46% of adults with pyelonephritis, compared with 68% for adults with cystitis. A common error was prescribing nitrofurantoin for a kidney infection, where it won’t reach the infection site.¹⁵ If you’ve been prescribed nitrofurantoin and your symptoms include fever, flank pain, or chills, it’s worth double-checking with your provider, because those symptoms suggest the infection may have reached the kidneys.

UTI Treatment During Pregnancy

Pregnancy adds layers of complexity because both the infection and the drug used to treat it can affect the developing baby. Untreated UTIs during pregnancy carry a higher risk of progressing to kidney infections and can trigger preterm labor, so treatment is always necessary.

Most antibiotics recommended for UTIs in pregnancy fall into what was formerly classified as FDA category B, meaning no adverse effects have been seen in well-controlled human studies.¹⁶ Nitrofurantoin, certain beta-lactam antibiotics, sulfonamides, and fosfomycin are all options. The first trimester introduces some caution: there are mixed data about possible associations between nitrofurantoin or sulfonamide use and congenital anomalies in early pregnancy, though the studies have significant limitations. The American College of Obstetricians and Gynecologists notes that nitrofurantoin and sulfonamides are still reasonable in the first trimester if no appropriate alternatives are available, and they can be used as first-line therapy in the second and third trimesters.¹⁷ People with a condition called G6PD deficiency should avoid nitrofurantoin due to a risk of hemolytic anemia.

UTIs in Men

UTIs are far less common in men than in women, and when they do occur, they are generally treated as complicated infections because the male anatomy makes simple bladder infections unusual. This typically means longer courses of antibiotics. A large U.S. outpatient study found that ciprofloxacin was prescribed in roughly 48% of male UTI cases, followed by TMP-SMX at about 25%, with nitrofurantoin at only about 8%.¹⁸ The average treatment duration was about 9 days, and only about half of male patients received what was considered the recommended first-choice therapy in terms of both drug selection and duration.

There is growing interest in whether narrower-spectrum antibiotics could work for men with lower UTIs as well. A Scandinavian register-based study compared men who received narrow-spectrum antibiotics (nitrofurantoin or pivmecillinam) with those who received broader-spectrum drugs. There was no difference in the rate of complications within 30 days, and the researchers concluded that narrow-spectrum antibiotics seemed like an optimal choice for preventing complications when treating men with lower UTIs.¹⁹ That said, men who received broader drugs had slightly lower odds of needing to come back for treatment failure or recurrence, so the trade-off isn’t entirely clear-cut.

When E. coli Isn’t the Culprit

E. coli causes the majority of UTIs, and the first-line recommendations are built around that assumption. But in certain groups, especially people with recurrent infections, the bacterial landscape shifts. A study of patients with recurrent lower UTIs found that gram-positive bacteria accounted for over 40% of cases. Many of those gram-positive species were resistant to nitrofurantoin in every tested sample, which is a problem if a doctor prescribes empirically based on the assumption that E. coli is to blame.²⁰

This is one reason why urine cultures matter more for recurrent or treatment-resistant infections than for a first-time, straightforward bladder infection. For an uncomplicated first UTI, guidelines generally support starting treatment empirically, based on what’s likely to be causing the infection in your area. But if you’ve had multiple UTIs, or if your symptoms aren’t improving on the prescribed antibiotic, a culture can identify the specific organism and which drugs it responds to. The shift from “treat the assumed bug” to “treat the confirmed bug” becomes increasingly important the more UTIs you’ve had.

The Resistance Problem Up Close

Antibiotic resistance isn’t a hypothetical future threat for UTI treatment; it’s the reason the recommended drugs have already changed. Ampicillin, which was once widely used, now fails against roughly half of E. coli isolates.⁷ In England, trimethoprim resistance in some regions reaches 30% to 44%.²¹

Another layer of concern involves extended-spectrum beta-lactamase (ESBL)-producing bacteria. These are strains that can break down many common antibiotics, including most penicillins and cephalosporins. A global surveillance study found that about 18% of E. coli urinary isolates from hospitalized patients were ESBL-producers, with rates climbing above a quarter in parts of Asia and the Pacific. Among those ESBL-positive isolates, fewer than 16% were susceptible to ciprofloxacin or levofloxacin, meaning the fluoroquinolones barely worked at all for this group.²²

This is one of the main reasons guidelines emphasize choosing narrower antibiotics like nitrofurantoin when possible. Using a drug that concentrates only in the urine and doesn’t circulate systemically puts less selective pressure on bacteria elsewhere in the body, which theoretically slows the development of resistance. When broader drugs are used routinely for infections that don’t need them, the entire ecosystem of bacteria in your gut, skin, and urinary tract gets nudged toward resistance.

What Antibiotics Do to Your Gut Bacteria

Any antibiotic course disrupts the gut microbiome to some degree, and UTI antibiotics are no exception. A clinical trial testing a novel antibiotic for uncomplicated UTIs tracked microbiome changes across the gut, throat, and vaginal sites. By day five of treatment, there were significant drops in microbial diversity across all tested body sites, with the gut showing the biggest shift. The encouraging finding was that by the follow-up visit, diversity had largely returned to pre-treatment levels, and no concerning pathogenic bacteria had taken hold.²³

Not all antibiotics are equal on this front. Fluoroquinolones and TMP-SMX are broader in their reach and tend to cause more collateral microbiome damage than nitrofurantoin, which largely bypasses the gut. Fosfomycin’s single-dose regimen also limits the window of disruption. If you’ve had repeated antibiotic courses and are concerned about the cumulative effect on your gut health, these differences in microbiome impact are worth discussing with your doctor.

Preventing Recurrent UTIs Without Constant Antibiotics

For people who get UTIs repeatedly, the default approach for years was a low daily dose of antibiotics taken preventively. That works, but it raises concerns about long-term resistance and side effects. Several non-antibiotic strategies have evidence behind them.

Cranberry products have been studied extensively. The data suggest they reduce UTI recurrences by roughly 30% to 40% in premenopausal women with a history of recurrent infections, though they are less effective than daily low-dose antibiotics.²⁴ That’s a meaningful reduction for something with virtually no side effects, but it’s not a full replacement for people with very frequent infections.

A more interesting alternative is methenamine hippurate, an older drug that acidifies the urine and produces formaldehyde at concentrations that kill bacteria. A large, randomized trial found that methenamine hippurate was non-inferior to daily antibiotic prophylaxis for preventing recurrent UTIs over 12 months. The antibiotic group experienced about 0.89 UTI episodes per person per year, while the methenamine group experienced about 1.38, a difference the study considered within the acceptable range for non-inferiority.²⁵ The appeal is that methenamine hippurate doesn’t promote antibiotic resistance, making it a good fit for people who want to reduce their antibiotic exposure over time.

Delayed Prescribing and the Ibuprofen Question

There’s a small but growing body of research asking whether every uncomplicated UTI actually needs immediate antibiotics. The concept of delayed prescribing involves giving a patient a prescription but asking them to wait a day or two to see if symptoms improve on their own, possibly using a pain reliever like ibuprofen in the meantime. A literature review found that both antibiotic delay and ibuprofen were less effective than immediate antibiotics at early symptom relief and clearing the infection, but they still showed promise as alternatives in non-pregnant women with cystitis. These approaches reduced overall antibiotic use in primary care settings without leading to significant increases in kidney infections.²⁶

This isn’t advice to skip antibiotics if you have a UTI. It’s a description of an emerging clinical strategy where the goal is to identify patients whose infections might resolve without treatment, reducing unnecessary antibiotic exposure across the population. If you’re in significant pain, running a fever, or have any risk factors for complications, immediate treatment remains the standard. But if you have mild symptoms and your provider suggests watchful waiting with a backup prescription, the evidence suggests that approach is reasonable.

Side Effects Worth Knowing About

Each first-line antibiotic comes with its own set of potential downsides. Nitrofurantoin commonly causes nausea and gastrointestinal upset. Taking it with food helps considerably. In elderly patients or people who use it long-term for prevention, it has been linked to rare but serious lung and liver problems, which is why guidelines caution against extended use in older adults.¹

TMP-SMX can cause rashes, sometimes severe, and it has been associated with a higher overall rate of adverse events compared with some other UTI drug classes.²⁷ Fosfomycin’s single-dose format limits side-effect exposure, and its adverse event rate in meta-analyses has been comparable to other antibiotics used for the same purpose.⁴ The fluoroquinolone side-effect story, as described above, is the most dramatic: tendon rupture, peripheral neuropathy, and central nervous system effects that prompted FDA black-box warnings.

These aren’t reasons to be afraid of UTI antibiotics in general. The absolute risk of serious side effects from a short course of nitrofurantoin or fosfomycin is low. But they are reasons to avoid broad-spectrum drugs for a condition that narrow-spectrum ones handle well.

1
PubMed Central. Nitrofurantoin: properties and potential in treatment of urinary tract infection: a narrative review
2
PubMed Central. Clinical Practice Guidelines for the Antibiotic Treatment of Community-Acquired Urinary Tract Infections – Section: Acute uncomplicated cystitis
3
Oxford Academic (Open Forum Infectious Diseases). Outpatient Antibiotic Prescribing Practices for Uncomplicated Urinary Tract Infection in Women in the United States, 2002-2011
4
PubMed Central. Efficacy and Safety of Single-dose Fosfomycin for Uncomplicated Urinary Tract Infection in Women: Systematic Review and Meta-analysis
5
PubMed Central. Efficacy of Single Dose of Fosfomycin Versus a Five-Day Course of Ciprofloxacin in Patients With Uncomplicated Urinary Tract Infection
6
PubMed Central. Assessment of the Compliance of Cystitis Management According to French Recommendations through the Analysis of Prescriptions Collected in Community Pharmacies
7
PubMed Central. Trends in Antibiotic Resistance of Escherichia coli Strains Isolated from Clinical Samples (2019–2023): A Hospital-Based Retrospective Analysis
8
PubMed. Prediction of trimethoprim/sulfamethoxazole resistance in community-onset urinary tract infections
9
PubMed Central. Ciprofloxacin resistance in community- and hospital-acquired Escherichia coli urinary tract infections: a systematic review and meta-analysis of observational studies
10
Polish Archives of Internal Medicine. Recurrent lower urinary tract infections in adults: don’t think it is E. coli, don’t choose ciprofloxacin to treat
11
PLoS Pathogens. Wicked: The untold story of ciprofloxacin – Section: No good deed (goes unpunished)
12
International Journal of Antimicrobial Agents. A Critical Review of Cephalexin and Cefadroxil for the Treatment of Acute Uncomplicated Lower Urinary Tract Infection in the Era of “Bad Bugs, Few Drugs”
13
PubMed. Revisiting β-Lactams for Treatment of Urinary Tract Infections: Assessing Clinical Outcomes of Twice-Daily Cephalexin for Empiric Treatment of Uncomplicated Urinary Tract Infections
14
PubMed. Cystitis and Pyelonephritis: Diagnosis, Treatment, and Prevention
15
PubMed Central. Appropriateness of Antibiotic Prescriptions for Urinary Tract Infections
16
PubMed Central. Which Antibiotic for Urinary Tract Infections in Pregnancy? A Literature Review of International Guidelines
17
Obstetrics & Gynecology. Urinary Tract Infections in Pregnant Individuals – Section: Acute Cystitis
18
PubMed. Exploring variations in recommended first-choice therapy for complicated urinary tract infections in males: Insights from outpatient settings across age, race, and ethnicity
19
PubMed Central. Different antibiotic regimes in men diagnosed with lower urinary tract infection – a retrospective register-based study
20
Polish Archives of Internal Medicine. Etiology and bacterial susceptibility to antibiotics in patients with recurrent lower urinary tract infections
21
JAC-Antimicrobial Resistance. Resistance to empirical antibiotics in urinary tract infections caused by Enterobacterales in the East of England
22
PubMed. Antimicrobial susceptibility of global inpatient urinary tract isolates of Escherichia coli: results from the Study for Monitoring Antimicrobial Resistance Trends (SMART) program: 2009-2010
23
BioMed Central / BMC Microbiology. Microbiome recovery in adult females with uncomplicated urinary tract infections in a randomised phase 2A trial of the novel antibiotic gepotidacin (GSK140944)
24
PubMed Central. Non-Antibiotic Prophylaxis for Urinary Tract Infections
25
BMJ. Alternative to prophylactic antibiotics for the treatment of recurrent urinary tract infections in women: multicentre, open label, randomised, non-inferiority trial
26
PubMed. Delayed and Non-Antibiotic Therapy for Urinary Tract Infections: A Literature Review
27
PubMed. Antibiotic class comparisons for the treatment of pyelonephritis and complicated urinary tract infections: A systematic review and meta-analysis